Novartis Kymriah Receives First CD19 CAR-T Marketing Authorization in Europe
First CD19 CAR-T Commercialization in Europe
The European Union granted marketing authorization for Novartis AG's Kymriah (active ingredient: tisagenlecleucel) on August 23, 2018. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on June 27, 2018, marking a transition from clinical development to approval and commercialization. Kymriah is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that genetically modifies a patient's T-cells to recognize CD19 on B-cell cancers. It was approved alongside Gilead Sciences (GILD) and Kite's Yescarta (axicabtagene ciloleucel) on the same day, opening the first commercial pathway for CAR-T in Europe.
Expanded Authorization Scope with Three Indications
The current European indications include pediatric and young adult patients (under 25 years) with refractory, post-transplant relapsed, or second or later relapsed B-cell acute lymphoblastic leukemia (B-ALL); adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; and adult patients with follicular lymphoma (FL) in the same treatment line. In the initial pediatric and young adult B-ALL trial, approximately 66% of 92 patients achieved complete response within three months of treatment. Compared to existing options such as Blincyto (blinatumomab, CD19/CD3), Besponsa (inotuzumab ozogamicin, CD22), salvage chemotherapy, and hematopoietic stem cell transplantation, Kymriah offers a differentiated, single-dose cell therapy. However, due to risks of cytokine release syndrome (CRS), neurotoxicity, and severe infections, treatment must be administered in experienced centers with tocilizumab stockpiles.
Regulatory Precedent and Long-Term Safety Obligations
Kymriah became a representative case in the European Advanced Therapy Medicinal Product (ATMP) review process after receiving orphan drug and PRIME designation. The U.S. Food and Drug Administration (FDA) had previously approved the B-ALL indication on August 30, 2017, with the Cellular, Tissue, and Gene Therapies Advisory Committee voting 10-0 in favor of its benefit-risk profile. The European approval established a structure that evaluates manufacturing consistency, patient-specific vein-to-facility logistics, and treatment center certification as part of the product's value. In 2024, the EMA added a risk of secondary malignancies of T-cell origin to all CAR-T approvals and recommended lifelong monitoring, reinforcing the importance of long-term follow-up.
Commercialization Limitations Revealed by Intensifying Competition
In DLBCL, Yescarta and Bristol-Myers Squibb (BMY)'s Breyanzi (lisocabtagene maraleucel, CD19) are direct competitors, and in FL, Yescarta also targets the same CD19 pathway. As of 2024, six CAR-T therapies—Kymriah, Yescarta, Breyanzi, Tecartus, Abecma, and Carvykti—are approved in the European Union, reducing the initial scarcity of the market. According to Novartis disclosures, Kymriah's global sales were $508 million in 2023, $443 million in 2024, and $381 million in 2025, reflecting 13% and 14% declines, respectively. Therefore, while this approval validates the regulatory and clinical value of the platform, from an investment perspective, manufacturing turnaround time, treatment center capacity, and early-line entry of competing products will determine long-term growth potential.
The 2018 European approval transformed Kymriah from a clinical-stage asset into the first-generation CD19 CAR-T available for commercial use and established an industry standard that includes patient-specific manufacturing, logistics, and treatment center certification. For researchers, the approximately 66% complete response rate in the B-ALL trial and the 10-0 FDA advisory committee vote provide strong efficacy evidence, but lifelong monitoring for CRS, neurotoxicity, and secondary malignancies remains a key safety challenge. For the industry, competition in DLBCL and FL from Yescarta and Breyanzi, as well as treatment sequence competition with Blincyto, Besponsa, and hematopoietic stem cell transplantation, limits the accessible market. From an investment standpoint, Kymriah's 2025 sales of $381 million and a 14% year-over-year decline highlight that manufacturing efficiency, treatment center capacity, and indication-specific market share—not the approval itself—determine enterprise value. While the European cell therapy ecosystem is positively impacted in the long term, Novartis' short-term revenue momentum is weak, making a Watchlist rating appropriate.
Source: EMA (ema)